Merck & Co.

Idera has entered into an exclusive license and research collaboration agreement with Merck & Co., Inc. to research, develop and commercialize vaccine products containing Idera’s TLR7, 8 and 9 agonists in the fields of oncology, infectious diseases and Alzheimer's disease.

In the first quarter of 2012, Merck & Co. selected several novel agonists targeted to TLR7, TLR8 or TLR9 for evaluation and exclusive use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

Data from preclinical studies have appeared in peer-review scientific journals (Paper) (Paper) (Paper) and have been presented at various scientific conferences (Presentation).

Please click here for more information on this collaboration.